Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

NCT04584008 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms
Gastric Cancer
Esophageal Squamous Cell Carcinoma
Colorectal Cancer
Gastrointestinal Stromal Tumors
Pancreatic Cancer
Neuroendocrine Tumors
Unknown Primary Cancer
Digestive Cancer

Interventions

DRUG: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
DRUG: Other Therapy

Sponsor

Peking University

Collaborators

[object Object]
[object Object]